Almost half of colorectal cancer patients carry a mutation in the KRAS gene—a molecular switch that pushes normal cells into runaway growth. For years, researchers hoped that KRAS inhibitor drugs would be a game-changer, locking down this mutation and halting tumor expansion. But the victory has proven short-lived: these drugs work initially, then stop working. Now, scientists at Weill Cornell Medicine and MD Anderson Cancer Center have discovered why, and the answer isn't what they expected.
The breakthrough centers on inflammation—not genetic mutations—as the key to how tumors outsmart KRAS inhibitors. In a study published in Cancer Cell, researchers analyzed colorectal cancer biopsies from patients taken before, during, and after treatment. They expected to find tumors acquiring new genetic mutations to escape the drugs. Instead, they found something more surprising: most resistant tumors weren't relying on genetic changes at all. Some carried extra KRAS copies, but acquired mutations were rare. What they found instead was a coordinated, non-genetic response rooted in inflammatory pathways.
Dr. Lukas Dow, who led the study as a professor of biochemistry in medicine at Weill Cornell, described the finding as both unexpected and revealing. "The genetic changes often happen in only a small subset of cells, but the inflammatory adaptive response is more general," Dow explained. "When we inhibit that process in preclinical models, less drug resistance develops."
By analyzing hundreds of thousands of individual cells in tumor slices, the team observed a consistent pattern: transcripts related to inflammation rose sharply in malignant cells during the early phase of KRAS inhibitor treatment, then declined after resistance took hold. This suggested inflammation was a critical waystation on the road to drug resistance. To test whether the cancer cells themselves were driving this inflammatory response—rather than immune cells recruited to the tumor—the researchers turned to organoids, three-dimensional clusters of malignant colorectal cells grown in a laboratory dish without any other cell types present.
The organoids revealed a crucial insight: the same inflammation-linked gene expression spike occurred even in isolation, with no immune cells in the picture. This meant the cancer cells themselves, not the immune system, were orchestrating their own inflammatory response to the drug. When researchers blocked these inflammatory signals in KRAS inhibitor-treated organoids, drug resistance dropped noticeably.
"This result suggests that the drug is driving changes within the tumor cells that ultimately contribute to the emergence of resistance to that drug," Dow said.
The discovery opens a new therapeutic avenue. Rather than battling KRAS mutations alone, clinicians might combine KRAS inhibitors with anti-inflammatory treatments to prevent tumors from evolving resistance in the first place. Dr. Salvador Alonso, a co-first author now at MD Anderson's gastrointestinal medical oncology division, emphasized that understanding escape routes ahead of time could reshape treatment strategy. The research suggests that the next generation of colorectal cancer therapies might succeed not by pursuing mutations, but by cutting off the inflammatory pathway that allows tumors to adapt and survive.